Update on Joint Corporate Brokers in London

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Deutsche Bank AG (trading as Deutsche Numis) as its joint Corporate Broker in London with immediate effect following the termination of HSBC Bank plc as joint Corporate Broker. Panmure Liberum Limited and Cavendish Capital Markets Limited will continue to act as joint Corporate Brokers in London and Panmure Liberum Limited will continue to act as Nominated Advisor to HUTCHMED in London in respect of the AIM rules.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit www.hutch-med.com or follow us on LinkedIn.

CONTACTS